{"type":"trials","record":{"id":42022,"source_id":"clinicaltrials-gov","external_id":"NCT01089517","title":"A Safety and Efficacy Study of E10030 (Anti-PDGF Pegylated Aptamer) Plus Lucentis for Neovascular Age-Related Macular Degeneration","brief_summary":"The objectives of this study are to evaluate the safety and efficacy of E10030 intravitreous injection when administered in combination with Lucentis® against a control of Lucentis® alone in subjects with subfoveal choroidal neovascularization secondary to age-related macular degeneration (AMD).","overall_status":"Completed","phases":["PHASE2"],"study_type":"INTERVENTIONAL","sponsor":"Ophthotech Corporation","enrollment":449,"countries":["United States"],"start_date":"2010-03-01","completion_date":"2012-06-01","last_update_date":"2024-03-19","source_url":"https://clinicaltrials.gov/study/NCT01089517","editorial_summary":"A registered PHASE2 study indexed because it matched monitored longevity research terms. Registry status: Completed. Registration does not establish safety or effectiveness.","first_seen_at":"2026-09-25T01:25:30.378222+00:00","last_seen_at":"2026-09-25T06:20:47.789+00:00","metadata":{"sex":"ALL","acronym":null,"age_range":"50 Years to 100 Years","comparator":"Lucentis","organization":"Astellas Pharma Inc","interventions":["E10030 plus Lucentis","Lucentis"],"registry_source":"ClinicalTrials.gov","outcome_measures":["Mean Change in Visual Acuity From Baseline at the Week 24 Visit — 24 Weeks","The Proportion of Subjects Gaining 15 or More ETDRS Letters From Baseline at the Week 24 Visit — 24 weeks","Proportion of Patients With at Least 1 Adverse Event — 24 weeks"],"design_description":"RANDOMIZED · PARALLEL · TREATMENT · QUADRUPLE","source_has_results":true},"controlled_terms":["Age-Related Macular Degeneration","E10030 plus Lucentis","Lucentis"],"relevance_confidence":100,"source_quality_score":100,"freshness_score":65,"publication_state":"published","match_explanation":"Title contains controlled term: age-related macular degeneration.","quality_checked_at":"2026-09-25T06:20:59.355028+00:00","duplicate_cluster_key":"id:nct01089517","duplicate_of_id":null,"evidence_snapshot":{"status":"structured","version":1,"duration":"2010-03-01 to 2012-06-01","comparator":"Lucentis","confidence":"structured-source","population":"ALL · 50 Years to 100 Years","provenance":{"duration":"start_date and completion_date","comparator":"registry arm fields","population":"registry eligibility fields","intervention":"registry intervention fields","participants":"enrollment","study_design":"study_type and registry design fields","evidence_stage":"phases","reported_outcome":"not available","outcomes_measured":"registry outcome-measure fields"},"generated_at":"2026-09-25T06:20:47.908Z","intervention":["E10030 plus Lucentis","Lucentis"],"participants":449,"study_design":"RANDOMIZED · PARALLEL · TREATMENT · QUADRUPLE","subject_scope":"Human clinical study registration","evidence_stage":"PHASE2","safety_context":"Eligibility, adverse-event details, and clinical decisions must be checked in the official registry and with qualified clinicians.","source_support":"Structured registry protocol metadata; no finding-level conclusion is generated.","main_limitation":"This is a study registration. No reusable structured result is available here, so it cannot show whether the intervention worked or was safe.","reported_outcome":null,"outcomes_measured":["Mean Change in Visual Acuity From Baseline at the Week 24 Visit — 24 Weeks","The Proportion of Subjects Gaining 15 or More ETDRS Letters From Baseline at the Week 24 Visit — 24 weeks","Proportion of Patients With at Least 1 Adverse Event — 24 weeks"],"regulatory_context":"Trial registration is not regulatory approval and does not establish that an intervention is available."},"clinical_trial_topics":[{"topic_slug":"vision-aging","is_published":true,"match_reasons":["Title contains controlled term: age-related macular degeneration.","Abstract contains controlled term: age-related macular degeneration.","Source terminology contains: age-related macular degeneration.","Title supplies longevity context: age-related.","Study type is explicitly identified as INTERVENTIONAL."],"matched_fields":["title","abstract","controlled terminology","title context","study type"],"relevance_score":100,"intelligence_topics":{"name":"Vision ageing","slug":"vision-aging"}}],"content_sources":{"name":"ClinicalTrials.gov","homepage_url":"https://clinicaltrials.gov/"}},"canonical_url":"https://www.immortal.life/trials/42022","automation_disclosure":"Generated automatically from cited source metadata. No scientist, clinician, researcher, editor, or human reviewer evaluates this publication before release."}